Eledon Pharmaceuticals Inc
NASDAQ:ELDN

Watchlist Manager
Eledon Pharmaceuticals Inc Logo
Eledon Pharmaceuticals Inc
NASDAQ:ELDN
Watchlist
Price: 4.0677 USD -4.74%
Market Cap: 161.3m USD
Have any thoughts about
Eledon Pharmaceuticals Inc?
Write Note

Intrinsic Value

ELDN's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one ELDN stock under the Base Case scenario is 2.1082 USD. Compared to the current market price of 4.0677 USD, Eledon Pharmaceuticals Inc is Overvalued by 48%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ELDN Intrinsic Value
2.1082 USD
Overvaluation 48%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Eledon Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ELDN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ELDN?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Eledon Pharmaceuticals Inc

Provide an overview of the primary business activities
of Eledon Pharmaceuticals Inc.

What unique competitive advantages
does Eledon Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Eledon Pharmaceuticals Inc face in the near future?

Summarize the latest earnings call
of Eledon Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Eledon Pharmaceuticals Inc.

Provide P/S
for Eledon Pharmaceuticals Inc.

Provide P/E
for Eledon Pharmaceuticals Inc.

Provide P/OCF
for Eledon Pharmaceuticals Inc.

Provide P/FCFE
for Eledon Pharmaceuticals Inc.

Provide P/B
for Eledon Pharmaceuticals Inc.

Provide EV/S
for Eledon Pharmaceuticals Inc.

Provide EV/GP
for Eledon Pharmaceuticals Inc.

Provide EV/EBITDA
for Eledon Pharmaceuticals Inc.

Provide EV/EBIT
for Eledon Pharmaceuticals Inc.

Provide EV/OCF
for Eledon Pharmaceuticals Inc.

Provide EV/FCFF
for Eledon Pharmaceuticals Inc.

Provide EV/IC
for Eledon Pharmaceuticals Inc.

Show me price targets
for Eledon Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Eledon Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Eledon Pharmaceuticals Inc?

What are the Net Income projections
for Eledon Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Eledon Pharmaceuticals Inc?

What are the EPS projections
for Eledon Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Eledon Pharmaceuticals Inc?

What are the EBIT projections
for Eledon Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Eledon Pharmaceuticals Inc?

Compare the revenue forecasts
for Eledon Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Eledon Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Eledon Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Eledon Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Eledon Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Eledon Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Eledon Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Eledon Pharmaceuticals Inc.

Provide ROE
for Eledon Pharmaceuticals Inc.

Provide ROA
for Eledon Pharmaceuticals Inc.

Provide ROIC
for Eledon Pharmaceuticals Inc.

Provide ROCE
for Eledon Pharmaceuticals Inc.

Provide Gross Margin
for Eledon Pharmaceuticals Inc.

Provide Operating Margin
for Eledon Pharmaceuticals Inc.

Provide Net Margin
for Eledon Pharmaceuticals Inc.

Provide FCF Margin
for Eledon Pharmaceuticals Inc.

Show all solvency ratios
for Eledon Pharmaceuticals Inc.

Provide D/E Ratio
for Eledon Pharmaceuticals Inc.

Provide D/A Ratio
for Eledon Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Eledon Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Eledon Pharmaceuticals Inc.

Provide Quick Ratio
for Eledon Pharmaceuticals Inc.

Provide Current Ratio
for Eledon Pharmaceuticals Inc.

Provide Cash Ratio
for Eledon Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Eledon Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Eledon Pharmaceuticals Inc?

What is the current Free Cash Flow
of Eledon Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Eledon Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Eledon Pharmaceuticals Inc

Current Assets 87.2m
Cash & Short-Term Investments 83.6m
Other Current Assets 3.6m
Non-Current Assets 33.3m
PP&E 621k
Intangibles 32.4m
Other Non-Current Assets 255k
Current Liabilities 6m
Accounts Payable 2.1m
Accrued Liabilities 3.9m
Non-Current Liabilities 123m
Other Non-Current Liabilities 123m
Efficiency

Earnings Waterfall
Eledon Pharmaceuticals Inc

Revenue
0 USD
Operating Expenses
-46.9m USD
Operating Income
-46.9m USD
Other Expenses
-41.6m USD
Net Income
-88.5m USD

Free Cash Flow Analysis
Eledon Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ELDN Profitability Score
Profitability Due Diligence

Eledon Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

Eledon Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

ELDN Solvency Score
Solvency Due Diligence

Eledon Pharmaceuticals Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
53/100
Solvency
Score

Eledon Pharmaceuticals Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ELDN Price Targets Summary
Eledon Pharmaceuticals Inc

Wall Street analysts forecast ELDN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ELDN is 14.28 USD with a low forecast of 7.07 USD and a high forecast of 29.4 USD.

Lowest
Price Target
7.07 USD
74% Upside
Average
Price Target
14.28 USD
251% Upside
Highest
Price Target
29.4 USD
623% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ELDN?

Click here to dive deeper.

Dividends

Eledon Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ELDN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Eledon Pharmaceuticals Inc Logo
Eledon Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

156.7m USD

Dividend Yield

0%

Description

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 12 full-time employees. The company went IPO on 2014-09-17. The firm is focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS). Its lead compound in development is AT-1501, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand (CD40L, also called CD154). AT-1501 is engineered to improve both safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. Blocking CD40L inhibits both CD40 and CD11 costimulatory signaling pathways with the potential for better efficacy. The company is focused on developing AT-1501 in up to four indications: ALS, prevention of kidney allograft rejection, prevention of islet cell allograft rejection, and IgA Nephropathy (IgAN). The company has completed a Phase Ia/Ib single ascending dose trial in volunteers and people with amyotrophic lateral sclerosis (ALS).

Contact

CALIFORNIA
Irvine
19900 MacArthur Blvd Ste 550
+19492388090.0
eledon.com

IPO

2014-09-17

Employees

12

Officers

CEO & Non Independent Director
Dr. David-Alexandre C. Gros M.D., Ph.D.
President, Chief Scientific Officer & Non Independent Director
Dr. Steven N. Perrin Ph.D.
Chief Financial Officer
Mr. Paul Sean Little
Vice President of Technical Operations
Mr. John Herberger
General Counsel, Corporate Secretary & Chief Compliance Officer
Mr. Bryan E. Smith J.D.
Chief Regulatory Officer
Dr. David Hovland Ph.D.
Show More
Chief Medical Officer
Dr. Eliezer Katz F.A.C.S., FACS, M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one ELDN stock?

The intrinsic value of one ELDN stock under the Base Case scenario is 2.1082 USD.

Is ELDN stock undervalued or overvalued?

Compared to the current market price of 4.0677 USD, Eledon Pharmaceuticals Inc is Overvalued by 48%.

Back to Top